PET-adapted BrECADD versus escBEACOPP in Hodgkin Lymphoma
Graham Collins, Associate Professor, Haematology and lymphoma specialist at Oxford Cancer and Haematology centre, shared a paper by Peter Borchmann et al. on X, adding:
“Front line treatment of Hodgkin Lymphoma with PET-adapted BrECADD versus escBEACOPP. BrECADD wins the day.
Can it be beaten…?”
Source: Graham Collins/X
Authors: Peter Borchmann, Justin Ferdinandus, Gundolf Schneider, Alden Moccia, Richard Greil, Mark Hertzberg, Valdete Schaub, Andreas Hüttmann, Felix Keil, Judith Dierlamm, Mathias Hänel, Urban Novak, Julia Meissner, Andreas Zimmermann, Stephan Mathas, Josée M Zijlstra, Alexander Fosså, Andreas Viardot, Bernd Hertenstein, Sonja Martin, Pratyush Giri, Sebastian Scholl, Max S Topp, Wolfram Jung, Vladan Vucinic, Hans-Joachim Beck, Andrea Kerkhoff, Benjamin Unger, Andreas Rank, Roland Schroers, Christian Meyer zum Büschenfelde, Maike de Wit, Karolin Trautmann-Grill, Peter Kamper, Daniel Molin, Stefanie Kreissl, Helen Kaul, Dipl-Math, Bastian von Tresckow, Sven Borchmann, Karolin Behringer, Michael Fuchs, Andreas Rosenwald, Wolfram Klapper, L Hans-Theodor Eich, Christian Baues, Athanasios Zomas, Michael Hallek, Markus Dietlein, Carsten Kobe, and Volker Diehl.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023